Can SARS-CoV-2 infection cause diabetes? COVID19 infection diabetesrisk populationbasedstudy publichealth vaccination longtermcomplications BritishColumbia Canada SARSCoV2 JAMANetworkOpen
By Neha MathurApr 19 2023Reviewed by Lily Ramsey, LLM In a recent study published in the journal JAMA Network Open, researchers performed a cohort study between January 1, 2020, and December 31, 2021, in British Columbia, Canada, to assess the association between severe acute respiratory syndrome coronavirus 2 infection and incident diabetes.
However, it is unknown whether coronavirus disease 2019 is associated with transient hyperglycemia during active infection or whether these metabolic alterations persist over time, increasing the risk of incident diabetes among infected individuals. Most published studies evaluating the association between SARS-CoV-2 infection and incident diabetes used relatively small samples and fetched limited outcome ascertainment.
All eligible adult participants tested COVID-19-positive during the study duration on a real-time reverse transcription-polymerase chain reaction assay. The team created a matched control cohort with people who tested COVID-19-negative based on sociodemographic variables, such as gender, age , and RT-PCR sample collection date at a 1:4 ratio. Other covariates measured in this analysis were preexisting chronic conditions and vaccination status.
Results The final analytic sample of this study comprised 629,935 individuals with a median age of 32 years. Of these, 51.2% were females, and the rest were males. The number of individuals exposed to SARS-CoV-2 was 125,987, while the remaining 503,948 individuals remained unexposed.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Unravelling the factors influencing host tropism of SARS-CoV-2-related bat coronavirusesUnravelling the factors influencing host tropism of SARS-CoV-2-related bat coronaviruses biorxivpreprint tropism zoonosis covid SARSCoV2 bats COVID19 coronavirus host research
Read more »
Understanding the probable transmission of SARS-CoV-2 from lion to zookeepersUnderstanding the probable transmission of SARS-CoV-2 from lion to zookeepers CDC_NCEZID PotawatomiZoo covid COVID19 SARSCoV2 lion zoonotic zoonosis transmission disease outbreak pandemic
Read more »
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity - Nature CommunicationsWhilst SARS-CoV-2 mRNA vaccines have demonstrated efficacy in reducing infection severity, research has shown that SARS-CoV-2 infection is associated with new autoantibodies. Whether this would also be observed during mRNA vaccination is unclear. Here, the authors use an autoantibody screening platform to monitor autoantibody responses in a diverse cohort during vaccination.
Read more »
A modeling-based approach to optimize COVID-19 vaccine dosing schedules for improved protectionWhile the development of different vaccines has slowed the dissemination of SARS-CoV-2, the occurrence of breakthrough infections continues to fuel the pandemic. As a strategy to secure at least partial protection, with a single dose of a given COVID-19 vaccine to maximum possible fraction of the population, delayed administration of subsequent doses (or boosters) has been implemented in many countries. However, waning immunity and emergence of new variants of SARS-CoV-2 suggest that such measures may jeopardize the attainment of herd immunity due to intermittent lapses in protection. Optimizing vaccine dosing schedules could thus make the difference between periodic occurrence of breakthrough infections or effective control of the pandemic. To this end, we have developed a mechanistic mathematical model of adaptive immune response to vaccines and demonstrated its applicability to COVID-19 mRNA vaccines as a proof-of-concept for future outbreaks. The model was thoroughly calibrated against multiple clinical datasets involving immune response to SARS-CoV-2 infection and mRNA vaccines in healthy and immunocompromised subjects (cancer patients undergoing therapy); the model showed robust clinical validation by accurately predicting neutralizing antibody kinetics, a correlate of vaccine-induced protection, in response to multiple doses of mRNA vaccines. Importantly, we estimated population vulnerability to breakthrough infections and predicted tailored vaccination dosing schedules to maximize protection and thus minimize breakthrough infections, based on the immune status of a sub-population. We have identified a critical waiting window for cancer patients (or, immunocompromised subjects) to allow recovery of the immune system (particularly CD4+ T-cells) for effective differentiation of B-cells to produce neutralizing antibodies and thus achieve optimal vaccine efficacy against variants of concern, especially between the first and second doses. Also, we have obtained op
Read more »
A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates - Nature CommunicationsHere the authors develop a ferritin-based protein nanoparticle vaccine candidate for SARS-CoV-2, and show induction of neutralizing antibodies to variants of concern, including Omicron BQ.1, in non-human primates after initial immunization and a booster dose.
Read more »
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 - Genome MedicineBackground We previously reported that impaired type I IFN activity, due to inborn errors of TLR3- and TLR7-dependent type I interferon (IFN) immunity or to autoantibodies against type I IFN, account for 15–20% of cases of life-threatening COVID-19 in unvaccinated patients. Therefore, the determinants of life-threatening COVID-19 remain to be identified in ~ 80% of cases. Methods We report here a genome-wide rare variant burden association analysis in 3269 unvaccinated patients with life-threatening COVID-19, and 1373 unvaccinated SARS-CoV-2-infected individuals without pneumonia. Among the 928 patients tested for autoantibodies against type I IFN, a quarter (234) were positive and were excluded. Results No gene reached genome-wide significance. Under a recessive model, the most significant gene with at-risk variants was TLR7, with an OR of 27.68 (95%CI 1.5–528.7, P = 1.1 × 10−4) for biochemically loss-of-function (bLOF) variants. We replicated the enrichment in rare predicted LOF (pLOF) variants at 13 influenza susceptibility loci involved in TLR3-dependent type I IFN immunity (OR = 3.70[95%CI 1.3–8.2], P = 2.1 × 10−4). This enrichment was further strengthened by (1) adding the recently reported TYK2 and TLR7 COVID-19 loci, particularly under a recessive model (OR = 19.65[95%CI 2.1–2635.4], P = 3.4 × 10−3), and (2) considering as pLOF branchpoint variants with potentially strong impacts on splicing among the 15 loci (OR = 4.40[9%CI 2.3–8.4], P = 7.7 × 10−8). Finally, the patients with pLOF/bLOF variants at these 15 loci were significantly younger (mean age [SD] = 43.3 [20.3] years) than the other patients (56.0 [17.3] years; P = 1.68 × 10−5). Conclusions Rare variants of TLR3- and TLR7-dependent type I IFN immunity genes can underlie life-threatening COVID-19, particularly with recessive inheritance, in patients under 60 years old.
Read more »